{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:40:31Z","timestamp":1792280431660,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10096-026-05570-w","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:37:39Z","timestamp":1782776259000},"page":"3057-3067","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breaking barriers: Implementation of a tuberculosis preventive treatment protocol among newly eligible populations with promising results"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-1927","authenticated-orcid":false,"given":"Paloma","family":"Gij\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4374-6940","authenticated-orcid":false,"given":"Teresa","family":"Ald\u00e1miz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2727-1707","authenticated-orcid":false,"given":"Ana Isabel","family":"Ramos-Lisbona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8942-7495","authenticated-orcid":false,"given":"Flor","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8515-7434","authenticated-orcid":false,"given":"Cristina","family":"Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6389-0018","authenticated-orcid":false,"given":"Raquel","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-5583","authenticated-orcid":false,"given":"Patricia","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2600-2771","authenticated-orcid":false,"given":"Maria Jesus","family":"Ruiz-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"5570_CR1","unstructured":"World Health Organization Global tuberculosis report (2024) WHO, Geneva Available from: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/data. Accessed June 2025"},{"issue":"10","key":"5570_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"RM Houben","year":"2016","unstructured":"Houben RM, Dodd PJ (2016) The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med 13(10):e1002152. https:\/\/doi.org\/10.1371\/journal.pmed.1002152","journal-title":"PLoS Med"},{"issue":"3","key":"5570_CR3","doi-asserted-by":"publisher","first-page":"1900655","DOI":"10.1183\/13993003","volume":"54","author":"AMV Cohen","year":"2019","unstructured":"Cohen AMV, Sch\u00f6n T, Wejse C (2019) The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 54(3):1900655. https:\/\/doi.org\/10.1183\/13993003","journal-title":"Eur Respir J"},{"issue":"3","key":"5570_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/tropicalmed7030048","volume":"7","author":"NF Khabibullina","year":"2022","unstructured":"Khabibullina NF, Kutuzova DM, Burmistrova IA, Lyadova IV (2022) The biological and clinical aspects of a latent tuberculosis infection. Trop Med Infect Dis7(3):48. https:\/\/doi.org\/10.3390\/tropicalmed7030048","journal-title":"Trop Med Infect Dis"},{"key":"5570_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m5","volume":"368","author":"JRWN Campbell","year":"2020","unstructured":"Campbell JRWN, Menzies D (2020) Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ 368:m549. https:\/\/doi.org\/10.1136\/bmj.m5","journal-title":"BMJ"},{"issue":"1","key":"5570_CR6","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.ijid.2022.02.047","volume":"124","author":"DDG Goletti","year":"2022","unstructured":"Goletti DDG, Matteelli A, Migliori GB (2022) The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. Int J Infect Dis124(1):S12\u2013S19. https:\/\/doi.org\/10.1016\/j.ijid.2022.02.047","journal-title":"Int J Infect Dis"},{"issue":"3","key":"5570_CR7","doi-asserted-by":"publisher","first-page":"L412","DOI":"10.1152\/ajplung.00217.2021","volume":"322","author":"B Kestler","year":"2022","unstructured":"Kestler BTSdaP, PMC8934672 (2022) Latent tuberculosis testing through the ages: the search for a sleeping killer. Am J Physiol Lung Cell Mol Physiol 322(3):L412\u2013L9. https:\/\/doi.org\/10.1152\/ajplung.00217.2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"5570_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"MZA Pai","year":"2008","unstructured":"Pai MZA, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149:77\u201384. https:\/\/doi.org\/10.7326\/0003-4819-149-3-200808050-00241","journal-title":"Ann Intern Med"},{"issue":"6","key":"5570_CR9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S2213-2600(24)00028-6","volume":"12","author":"AK Coussens","year":"2024","unstructured":"Coussens AK, Zaidi SMA, Allwood BW, Dewan PK, Gray G, Kohli M et al (2024) Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise. Lancet Respir Med 12(6):484\u2013498. https:\/\/doi.org\/10.1016\/S2213-2600(24)00028-6","journal-title":"Lancet Respir Med"},{"issue":"1","key":"5570_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1164\/artpd.1956.73.1.1","volume":"73","author":"SH Ferebee","year":"1956","unstructured":"Ferebee SH, Palmer CE (1956) Prevention of experimental tuberculosis with isoniazid. Am Rev Tuberc 1\/956 Jan;73(1):7(1):1\u201318 https:\/\/doi.org\/10.1164\/artpd.1956.73.1.1","journal-title":"Am Rev Tuberc"},{"issue":"6","key":"5570_CR11","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/arrd.1967.95.6.935","volume":"95","author":"GW Comstock","year":"1967","unstructured":"Comstock GW, Ferebee SH, Hammes LM (1967) A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 95(6):935\u2013943. https:\/\/doi.org\/10.1164\/arrd.1967.95.6.935","journal-title":"Am Rev Respir Dis"},{"issue":"3","key":"5570_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1183\/09031936.05.00047805","volume":"26","author":"R Diel","year":"2005","unstructured":"Diel R, Nienhaus A, Schaberg T (2005) Cost-effectiveness of isoniazid chemoprevention in close contacts. Eur Respir J 26(3):465\u2013473. https:\/\/doi.org\/10.1183\/09031936.05.00047805","journal-title":"Eur Respir J"},{"issue":"11","key":"5570_CR13","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","volume":"281","author":"CM Nolan","year":"1999","unstructured":"Nolan CM, Goldberg SV, Buskin SE (1999) Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 281(11):1014\u20131018. https:\/\/doi.org\/10.1001\/jama.281.11.1014","journal-title":"JAMA"},{"issue":"6","key":"5570_CR14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1164\/arrd.1978.117.6.991","volume":"117","author":"DE Kopanoff","year":"1978","unstructured":"Kopanoff DE, Snider DE Jr, Caras GJ (1978) Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 117(6):991\u20131001. https:\/\/doi.org\/10.1164\/arrd.1978.117.6.991","journal-title":"Am Rev Respir Dis"},{"issue":"10","key":"5570_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1097\/00002030-199310000-00007","volume":"7","author":"A Guelar","year":"1993","unstructured":"Guelar A, Gatell JM, Verdejo J, Podzamczer D, Lozano L, Aznar E et al (1993) A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 7(10):1345\u20131349. https:\/\/doi.org\/10.1097\/00002030-199310000-00007","journal-title":"AIDS"},{"key":"5570_CR16","doi-asserted-by":"publisher","unstructured":"Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. (1993) Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 342(8866 ):268\u201372. https:\/\/doi.org\/10.1016\/0140-6736(93)91817-6","DOI":"10.1016\/0140-6736(93)91817-6"},{"issue":"8","key":"5570_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.eimc.2008.10.008","volume":"27","author":"JM Aguado","year":"2009","unstructured":"Aguado JM, Torre-Cisneros J, Fort\u00fan J, Benito N, Meije Y, Doblas A, Mu\u00f1oz P (2009) Documento de consenso para el tratamiento de la tuberculosis en pacientes con trasplante de \u00f3rgano s\u00f3lido [Consensus document for the management of tuberculosis in solid organ transplant recipients]. Enferm Infecc Microbiol Clin 27(8):465\u2013473 Spanish. https:\/\/doi.org\/10.1016\/j.eimc.2008.10.008","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"5570_CR18","unstructured":"World Health Organization (2020) WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. World Health Organization. https:\/\/iris.who.int\/handle\/10665\/331170. Accessed 19 July 2023"},{"key":"5570_CR19","doi-asserted-by":"publisher","unstructured":"Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J et al (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7(12):845\u2013855. https:\/\/doi.org\/10.1038\/nrmicro2236","DOI":"10.1038\/nrmicro2236"},{"issue":"5","key":"5570_CR20","doi-asserted-by":"publisher","first-page":"297.e1","DOI":"10.1016\/j.eimc.2010.02.006","volume":"28","author":"J Gonz\u00e1lez-Mart\u00edn","year":"2010","unstructured":"Gonz\u00e1lez-Mart\u00edn J, Garc\u00eda-Garc\u00eda JM, Anibarro L, Vidal R, Esteban J, Blanquer R et al (2010) Documento de consenso sobre diagn\u00f3stico, tratamiento y prevenci\u00f3n de la tuberculosis. Enferm Infecc Microbiol Clin 28(5):297.e1\u201320. https:\/\/doi.org\/10.1016\/j.eimc.2010.02.006","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"6","key":"5570_CR21","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L, G\u00f3mez-Reino JJ, Rodr\u00edguez-Valverde V, Montero D, Pascual-G\u00f3mez E, Mola EM et al (2005) BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52(6):1766\u20131772. https:\/\/doi.org\/10.1002\/art.21043","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5570_CR22","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1183\/09031936.00214014","volume":"45","author":"K L\u00f6nnroth","year":"2015","unstructured":"L\u00f6nnroth K, Migliori GB, Abubakar I, D\u2019Ambrosio L, de Vries G, Diel R, Douglas P et al (2015) Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 45(4):928\u201352. https:\/\/doi.org\/10.1183\/09031936.00214014","journal-title":"Eur Respir J"},{"issue":"2","key":"5570_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TNMI7-0039-2","volume":"5","author":"CA Haley","year":"2017","unstructured":"Haley CA (2017) Treatment of latent tuberculosis infection. Microbiol Spectr 5(2):10.1128\/microbiolspec.tnmi7-0039-2016. https:\/\/doi.org\/10.1128\/microbiolspec.TNMI7-0039-2","journal-title":"Microbiol Spectr"},{"key":"5570_CR24","unstructured":"Prevention ECfD IGO (2024) Tuberculosis surveillance and monitoring in Europe 2024\u20132022 data. Copenhagen: WHO Regional Office for Europe and Stockholm. Licence: CC BY 3.0"},{"issue":"6","key":"5570_CR25","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","volume":"46","author":"H Getahun","year":"2015","unstructured":"Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D et al (2015) Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 46(6):1563\u201376. https:\/\/doi.org\/10.1183\/13993003.01245-2015","journal-title":"Eur Respir J"},{"issue":"2","key":"5570_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/cid\/ciad246","volume":"77","author":"L Melnychuk","year":"2023","unstructured":"Melnychuk L, Perlman-Arrow S, Lisboa Bastos M, Menzies D (2023) A systematic review and meta-analysis of tuberculous preventive therapy adverse events. Clin Infect Dis 77(2):287\u2013294. https:\/\/doi.org\/10.1093\/cid\/ciad246","journal-title":"Clin Infect Dis"},{"issue":"5","key":"5570_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","volume":"379","author":"D Menzies","year":"2018","unstructured":"Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H et al (2018) Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 379(5):440\u2013453. https:\/\/doi.org\/10.1056\/NEJMoa1714283","journal-title":"N Engl J Med"},{"issue":"5","key":"5570_CR28","doi-asserted-by":"publisher","first-page":"e1064","DOI":"10.1093\/cid\/ciaa1741","volume":"73","author":"HL Huang","year":"2021","unstructured":"Huang HL, Lee MR, Cheng MH, Lu PL, Huang CK, Sheu CC et al (2021) Impact of age on outcome of rifapentine-based weekly therapy for latent tuberculosis infection. Clin Infect Dis 73(5):e1064\u2013e1071. https:\/\/doi.org\/10.1093\/cid\/ciaa1741","journal-title":"Clin Infect Dis"},{"issue":"9","key":"5570_CR29","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(23)00096-6","volume":"11","author":"N Winters","year":"2023","unstructured":"Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE (2023) Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysisLancet. Respir Med 11(9):782\u2013790. https:\/\/doi.org\/10.1016\/S2213-2600(23)00096-6","journal-title":"Respir Med"},{"issue":"1","key":"5570_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-10733-9","volume":"21","author":"K Sullivan","year":"2021","unstructured":"Sullivan K, Pease C, Zwerling A, Mallick R, Van Dyk D, Mulpuru S et al (2021) Seven-year retrospective study understanding the latent TB infection treatment cascade of care among adults in a low-incidence country. BMC Public Health 21(1):964. https:\/\/doi.org\/10.1186\/s12889-021-10733-9","journal-title":"BMC Public Health"},{"key":"5570_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12879","volume":"16","author":"A Sandgren","year":"2016","unstructured":"Sandgren A, Vonk Noordegraaf-Schouten M, van Kessel F, Stuurman A, Oordt-Speets A, van der Werf MJ (2016) Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis 16:204. https:\/\/doi.org\/10.1186\/s12879-016-1550-y","journal-title":"BMC Infect Dis"},{"issue":"1","key":"5570_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5588\/ijtld.14.0373","volume":"19","author":"Y Hirsch-Moverman","year":"2015","unstructured":"Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, Blumberg HM, Venkatappa TK, Horsburgh CR, Colson PW, Tuberculosis Epidemiologic Studies Consortium (TBESC) (2015) Latent tuberculous infection in the United States and Canada: who completes treatment and why? Int J Tuberc Lung Dis 19(1):31\u201338. https:\/\/doi.org\/10.5588\/ijtld.14.0373","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"5570_CR33","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1183\/13993003.01397-2015","volume":"47","author":"CG Erkens","year":"2016","unstructured":"Erkens CG, Slump E, Verhagen M, Schimmel H, de Vries G, Cobelens F, van den Hof S (2016) Monitoring latent tuberculosis infection diagnosis and management in the Netherlands. Eur Respir J 47(5):1492\u2013501. https:\/\/doi.org\/10.1183\/13993003.01397-2015","journal-title":"Eur Respir J"},{"key":"5570_CR34","first-page":"e201808057","volume":"92","author":"V Ambrona de Marcos","year":"2018","unstructured":"Ambrona de Marcos V, Bach Foradada P, Alsed\u00e0 Graells M, Duque Jim\u00e9nez T, Delgado Roche E, Aguilar Ariza R et al (2018) Compliance of latent tuberculosis infection treatment in a cohort of TB contacts. Rev Esp Salud Publica 92:e201808057","journal-title":"Rev Esp Salud Publica"},{"issue":"4","key":"5570_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10096-019-03765-y","volume":"39","author":"A Sent\u00eds","year":"2013","unstructured":"Sent\u00eds A, Vasconcelos P, Machado RS, Cayl\u00e0 JA, Guxens M, Peixoto V et al (2013) Failure to complete treatment for latent tuberculosis infection in Portugal, 2013\u20132017: geographic-, sociodemographic-, and medical-associated factors. Eur J Clin Microbiol Infect Dis 39(4):647\u2013656. https:\/\/doi.org\/10.1007\/s10096-019-03765-y","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"5570_CR36","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12879-018-3468-z","volume":"18","author":"YL Schein","year":"2018","unstructured":"Schein YL, Madebo T, Andersen HE, Arnesen TM, Dyrhol-Riise AM, Tveiten H et al (2018) Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study. BMC Infect Dis 18(1):587. https:\/\/doi.org\/10.1186\/s12879-018-3468-z","journal-title":"BMC Infect Dis"},{"issue":"3","key":"5570_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed9030054","volume":"9","author":"P Plans-Rubi\u00f3","year":"2019","unstructured":"Plans-Rubi\u00f3 P, Godoy S, Toledo D, Dom\u00ednguez A, Cayl\u00e0 J, Parron I et al (2019) Factors associated with non-adherence to tuberculosis preventive treatment among adult contacts of pulmonary tuberculosis cases with latent tuberculosis infection in Catalonia, Spain, in 2019\u20132021. Trop Med Infect Dis 9(3):54. https:\/\/doi.org\/10.3390\/tropicalmed9030054","journal-title":"Trop Med Infect Dis"},{"issue":"4","key":"5570_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13603","volume":"23","author":"MD Grijota-Camino","year":"2021","unstructured":"Grijota-Camino MD, Montero N, Luque MJ, D\u00edaz-Jurado M, Sab\u00e9 N, P\u00e9rez-Recio S et al (2021) Tuberculosis prevention in patients undergoing kidney transplantation: a nurse-led program for screening and treatment. Transpl Infect Dis 23(4):e13603. https:\/\/doi.org\/10.1111\/tid.13603","journal-title":"Transpl Infect Dis"},{"issue":"8","key":"5570_CR39","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S2213-2600(24)00083-3","volume":"12","author":"L Martinez","year":"2024","unstructured":"Martinez L, Seddon JA, Horsburgh CR, Lange C, Mandalakas AM (2024) Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing studies. Lancet Respir Med 12(8):633\u2013641. https:\/\/doi.org\/10.1016\/S2213-2600(24)00083-3","journal-title":"Lancet Respir Med"},{"issue":"6","key":"5570_CR40","doi-asserted-by":"publisher","first-page":"e1252","DOI":"10.1093\/cid\/ciab209","volume":"73","author":"HL Huang","year":"2021","unstructured":"Huang HL, Huang WC, Lin KD, Liu SS, Lee MR, Cheng MH et al (2021) Completion rate and safety of programmatic screening and treatment for latent tuberculosis infection in elderly patients with poorly controlled diabetic mellitus: a prospective multicenter study. Clin Infect Dis 73(6):e1252\u2013e1260. https:\/\/doi.org\/10.1093\/cid\/ciab209","journal-title":"Clin Infect Dis"},{"key":"5570_CR41","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ijid.2020.05.009","volume":"96","author":"JY Feng","year":"2020","unstructured":"Feng JY, Huang WC, Lin SM, Wang TY, Lee SS, Shu CC et al (2020) Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-A prospective observational study in Taiwan. Int J Infect Dis 96:550\u2013557. https:\/\/doi.org\/10.1016\/j.ijid.2020.05.009","journal-title":"Int J Infect Dis"},{"issue":"9","key":"5570_CR42","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s12094-024-03433-4","volume":"26","author":"M Borreg\u00f3n","year":"2024","unstructured":"Borreg\u00f3n M, S\u00e1nchez D, Mart\u00ednez E (2024) Screening and treatment of latent tuberculosis in patients with solid tumors and systemic cancer therapy. Clin Transl Oncol 26(9):2109\u20132115. https:\/\/doi.org\/10.1007\/s12094-024-03433-4","journal-title":"Clin Transl Oncol"},{"key":"5570_CR43","doi-asserted-by":"publisher","unstructured":"Baddley JWCF, Goletti D, Gomez-Reino JJ, Mylonakis E, San-Juan R (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents). Clin Microbiol Infect 24:S10\u2013S20. https:\/\/doi.org\/10.1016\/j.cmi.2017.12.025","DOI":"10.1016\/j.cmi.2017.12.025"},{"issue":"Supplement 2","key":"5570_CR44","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","volume":"24","author":"Compromised Hosts (ESGICH)","year":"2018","unstructured":"Compromised Hosts (ESGICH) (2018) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents). Clin Microbiol Infect 24(Supplement 2):S10\u2013S20. https:\/\/doi.org\/10.1016\/j.cmi.2017.12.025","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"5570_CR45","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cmi.2017.12","volume":"24","author":"H Picchi","year":"2018","unstructured":"Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM et al (2018) Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clin Microbiol Infect 24(3):216\u2013218. https:\/\/doi.org\/10.1016\/j.cmi.2017.12","journal-title":"Clin Microbiol Infect"},{"key":"5570_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf628","author":"MT Murrill","year":"2025","unstructured":"Murrill MT, Vel\u00e1squez GE, Szumowski JD, Phillips A, Kim A, Yazdany J et al (2025) Tuberculosis infection screening recommendations for targeted immunotherapies: comparison of U.S. prescribing information, clinical resources and quality measures. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaf628","journal-title":"Clin Infect Dis"},{"issue":"12","key":"5570_CR47","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.5588\/ijtld.18.0340","volume":"22","author":"R van Crevel","year":"2018","unstructured":"van Crevel R, Koesoemadinata R, Hill PC, Harries AD (2018) Clinical management of combined tuberculosis and diabetes. Int J Tuberc Lung Dis 22(12):1404\u20131410. https:\/\/doi.org\/10.5588\/ijtld.18.0340","journal-title":"Int J Tuberc Lung Dis"},{"key":"5570_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.107914","volume":"156","author":"SH Oh","year":"2025","unstructured":"Oh SH, Lee J, Jo J, Kwon JW (2025) Adverse events of tuberculosis preventive therapy among individuals with latent tuberculosis infection: a nationwide cohort study in South Korea. Int J Infect Dis 156:107914. https:\/\/doi.org\/10.1016\/j.ijid.2025.107914","journal-title":"Int J Infect Dis"},{"key":"5570_CR49","unstructured":"Kunst HKK (2010). Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 14(1):1374\u20131381. PMID: 20937175."},{"issue":"5","key":"5570_CR50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1157\/13102265","volume":"25","author":"A Rivero","year":"2007","unstructured":"Rivero A, L\u00f3pez-Cort\u00e9s L, Castillo R, Verdejo J, Garc\u00eda MA, Mart\u00ednez-Marcos FJ et al (2007) Grupo Andaluz para el estudio de las Enfermedades Infecciosas (GAEI). Ensayo cl\u00ednico aleatorizado para evaluar tres pautas cortas de tratamiento de la infecci\u00f3n latente tuberculosa en pacientes infectados por el VIH [Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients]. Enferm Infecc Microbiol Clin 25(5):305\u2013310 Spanish. https:\/\/doi.org\/10.1157\/13102265","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"5","key":"5570_CR51","doi-asserted-by":"publisher","first-page":"e1064","DOI":"10.1093\/cid\/ciaa1741","volume":"73","author":"HL Huang","year":"2024","unstructured":"Huang HL, Lee MR, Cheng MH, Lu PL, Huang CK, Sheu CC et al (2024) Impact of age on outcome of rifapentine-based weekly therapy for latent tuberculosis infection. Clin Infect Dis 73(5):e1064\u2013e1071. https:\/\/doi.org\/10.1093\/cid\/ciaa1741","journal-title":"Clin Infect Dis"},{"issue":"9","key":"5570_CR52","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(23)000","volume":"11","author":"N Winters","year":"2023","unstructured":"Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE et al (2023) Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med 11(9):782\u2013790. https:\/\/doi.org\/10.1016\/S2213-2600(23)000","journal-title":"Lancet Respir Med"},{"issue":"11","key":"5570_CR53","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N et al (2019) One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med 380(11):1001\u20131011. https:\/\/doi.org\/10.1056\/NEJMoa1806808","journal-title":"N Engl J Med"},{"issue":"9","key":"5570_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057717","volume":"12","author":"MX Rangaka","year":"2022","unstructured":"Rangaka MX, Hamada Y, Duong T, Bern H, Calvert J, Francis M et al (2022) Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for an open-label, multicentre, randomised controlled trial. BMJ Open 12(9):e057717. https:\/\/doi.org\/10.1136\/bmjopen-2021-057717","journal-title":"BMJ Open"},{"key":"5570_CR55","unstructured":"Ministerio de Sanidad, Consumo y Bienestar Social (2019) Plan para la prevenci\u00f3n y control de la tuberculosis en Espa\u00f1a. https:\/\/www.sanidad.gob.es\/areas\/DCVIHT\/tuberculosis\/docs\/PlanTB2019.pdf"},{"key":"5570_CR56","doi-asserted-by":"publisher","unstructured":"Caminero JA, Anibarro L, Tabernero E, Alcaide F, P\u00e9rez-Mendoza G, Millet JP, Guna R, de Souza-Galv\u00e3o ML, L\u00f3pez-Roa P, S\u00e1nchez-Montalv\u00e1 A, Gull\u00f3n-Blanco JA, Gonz\u00e1lez-Gal\u00e1n V (2026) Recommendations on the diagnosis and treatment of tuberculosis infection: SEPAR\/SEIMC\/Spanish Ministry of Health consensus statement. Arch Bronconeumol. https:\/\/doi.org\/10.1016\/j.arbres","DOI":"10.1016\/j.arbres"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05570-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05570-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05570-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:02:48Z","timestamp":1792278168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05570-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5570"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05570-w","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethics committee (CEIC Gregorio Mara\u00f1\u00f3n, reference\u202fMICRO.HGUGM.2024-078) and conducted in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}